NuCana (NCNA) Competitors $1.27 -0.01 (-0.44%) (As of 12:00 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NCNA vs. SLGL, PMCB, AIM, NLSP, WENA, SNSE, TLPH, NKGN, AWH, and CDTShould you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Sol-Gel Technologies (SLGL), PharmaCyte Biotech (PMCB), AIM ImmunoTech (AIM), NLS Pharmaceutics (NLSP), ANEW Medical (WENA), Sensei Biotherapeutics (SNSE), Talphera (TLPH), NKGen Biotech (NKGN), Aspira Women's Health (AWH), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical products" industry. NuCana vs. Sol-Gel Technologies PharmaCyte Biotech AIM ImmunoTech NLS Pharmaceutics ANEW Medical Sensei Biotherapeutics Talphera NKGen Biotech Aspira Women's Health Conduit Pharmaceuticals Sol-Gel Technologies (NASDAQ:SLGL) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking. Do analysts prefer SLGL or NCNA? Sol-Gel Technologies currently has a consensus price target of $5.00, indicating a potential upside of 963.60%. NuCana has a consensus price target of $25.00, indicating a potential upside of 1,861.71%. Given NuCana's higher probable upside, analysts plainly believe NuCana is more favorable than Sol-Gel Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00NuCana 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to SLGL or NCNA? In the previous week, Sol-Gel Technologies had 8 more articles in the media than NuCana. MarketBeat recorded 8 mentions for Sol-Gel Technologies and 0 mentions for NuCana. Sol-Gel Technologies' average media sentiment score of 0.46 beat NuCana's score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Overall Sentiment Sol-Gel Technologies Neutral NuCana Neutral Is SLGL or NCNA more profitable? NuCana has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -81.75%. Sol-Gel Technologies' return on equity of -27.17% beat NuCana's return on equity.Company Net Margins Return on Equity Return on Assets Sol-Gel Technologies-81.75% -27.17% -22.49% NuCana N/A -222.73%-105.62% Do institutionals and insiders hold more shares of SLGL or NCNA? 26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 31.2% of NuCana shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable earnings and valuation, SLGL or NCNA? Sol-Gel Technologies has higher revenue and earnings than NuCana. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSol-Gel Technologies$1.55M8.45-$27.24M-$0.34-1.38NuCanaN/AN/A-$34.37M-$12.20-0.10 Does the MarketBeat Community believe in SLGL or NCNA? NuCana received 102 more outperform votes than Sol-Gel Technologies when rated by MarketBeat users. Likewise, 67.65% of users gave NuCana an outperform vote while only 63.40% of users gave Sol-Gel Technologies an outperform vote. CompanyUnderperformOutperformSol-Gel TechnologiesOutperform Votes14963.40% Underperform Votes8636.60% NuCanaOutperform Votes25167.65% Underperform Votes12032.35% Which has more risk and volatility, SLGL or NCNA? Sol-Gel Technologies has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, NuCana has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. SummarySol-Gel Technologies beats NuCana on 11 of the 17 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get NuCana News Delivered to You Automatically Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCNA vs. The Competition Export to ExcelMetricNuCanaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.41M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-0.1110.57134.3717.77Price / SalesN/A243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book0.155.474.674.68Net Income-$34.37M$153.61M$119.07M$226.08M7 Day Performance-16.77%-2.00%-1.83%-1.04%1 Month Performance-30.65%-7.47%-3.62%1.04%1 Year Performance-87.41%31.80%31.63%26.28% NuCana Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCNANuCana3.1773 of 5 stars$1.27-0.4%$25.00+1,861.7%-88.1%$3.36MN/A-0.1030SLGLSol-Gel Technologies3.6128 of 5 stars$0.47+6.6%$5.00+963.6%-68.5%$13.10M$1.55M-1.3050News CoverageGap DownPMCBPharmaCyte Biotech0.6488 of 5 stars$1.68-2.3%N/A-21.1%$12.90MN/A2.612AIMAIM ImmunoTech1.7374 of 5 stars$0.20-0.2%$3.00+1,403.0%-52.0%$12.72M$200,000.000.0020News CoverageNLSPNLS Pharmaceutics1.2066 of 5 stars$3.32+0.9%N/A+623.1%$12.68MN/A0.006Gap DownWENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpSNSESensei Biotherapeutics4.8056 of 5 stars$0.48-3.6%$4.33+803.0%-20.0%$12.07MN/A0.0040News CoverageTLPHTalphera2.6915 of 5 stars$0.70-0.2%$4.50+538.4%N/A$12.00M$650,000.000.0019Gap UpNKGNNKGen BiotechN/A$0.33+4.5%N/A-89.1%$11.56M$80,000.00-0.06N/AGap UpAWHAspira Women's Health1.533 of 5 stars$0.70-3.6%$4.40+525.0%-78.5%$11.31M$9.15M-0.64110Analyst ForecastCDTConduit PharmaceuticalsN/A$0.11+23.1%N/A-92.8%$10.91MN/A0.003News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies Sol-Gel Technologies Competitors PharmaCyte Biotech Competitors AIM ImmunoTech Competitors NLS Pharmaceutics Competitors ANEW Medical Competitors Sensei Biotherapeutics Competitors Talphera Competitors NKGen Biotech Competitors Aspira Women's Health Competitors Conduit Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NCNA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana plc Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
